Medical proofs, social experiments clinical trials in shifting contexts

Medical Proofs, Social Experiments: Clinical Trials in Shifting Contexts

Volumn , Issue , 2010, Pages 1-189

  Will, Catherine ^a   Moreira, Tiago ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900128969     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (353)

1. Abraham, J. (1995). Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Development. London and New York: Routledge.
2. Abraham, J. (2007). Drug trials and evidence bases in international regulatory context. BioSocieties, 2(1): 41-56.
3. Abraham, J. and Lewis, G. (2000). Regulating Medicines in Europe: Competition, Expertise & Public Health. London: Routledge.
4. Abramson, J. (2004). Overdo$ed America: The Broken Promise of American Medicine. New York: HarperCollins.
5. Angell, M. (1988). Ethical Imperialism? Ethics in international collaborative clinical research. New England Journal of Medicine, 319: 1081-83.
6. Angell, M. (2004). The Truth About the Drug Companies: How they Deceive Us and What To Do About It. New York: Random House.
7. Armstrong, D. (2002). Clinical autonomy, individual and collective: The problem of changing doctors' behaviour. Social Science & Medicine, 55(10): 1771-7.
8. Armstrong, D. and Ogden, J. (2006). The role of etiquette and experimentation in explaining how doctors change behavior: a qualitative study, Sociology of Health and Illness, 28(7): 951-68.
9. Armstrong, D., Lilford, R., Ogden, J. and Wessely, S. (2007). Health-related quality of life and the transformation of symptoms. Sociology of Health and Illness, 29(4): 570-83.
10. Ashcroft, R. and ter Meulen, R. (2004). Ethics, philosophy and evidence based medicine. Journal of Medical Ethics, 30: 119.
11. Ashmore, M., Mulkay, M. and Pinch, T. (1989). Health and Efficiency: A Sociology of Health Economics. Milton Keynes: Open University Press.
12. Ballard, C.G. (2006). Presentation on Alzheimers Drugs. House of Commons, 16 January 2006.
13. Barry, A. (2001). Political Machines. London and New York: Athlone Press.
14. Baruch, G. (1981). Moral tales: parents' stories of encounters with the health professions. Sociology of Health & Illness, 3(3): 275-95.
15. Bauman, Z. (2007). Liquid Times. Living in an Age of Uncertainty. Cambridge: Polity Press.
16. Begg, C., Cho, M., Eastwood, S. et al. (1996). Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA, 276: 637-9.
17. Benatar, S.R. (2004). Towards progress in resolving dilemmas in international research ethics. Journal of Law, Medicine & Ethics, 32: 574-82.
18. Benatar, S.R., Singer, P.A., and Daar, A.S. (2005). Global challenges: the need for an expanded discourse on bioethics. PLoS Medicine, 2(7): e143. doi:10.1371/ journal.pmed.0020143
19. Benatar, S.R., and Fleisher, T.E. (2007). Ethical issues in research in low-income countries. International Journal of Tuberculosis & Lung Disease, 11(6): 617-23.
20. Berg, M. (1997). Rationalizing Medical Work: Decision Support Techniques and Medical Practices. Cambridge, MA: MIT Press.
21. Berg, M. (1995). Turning a practice into a science: reconceptualising postwar medical practice. Social Studies of Science, 25(3): 437-76.
22. Bernard, C. (1865). Introduction à L'étude de la médecine expérimentale. Paris: Ballière.
23. Bero, L.A., Roberto, G., Grimshaw, J.M., Harvey, E.J., Oxman, A., and Thomson, M.A. (1998). Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. British Medical Journal, 317(7156): 465-8.
24. Biehl, J. (2004). The activist state: Global pharmaceuticals, AIDS, and citizenship in Brazil. Social Text, 22(3): 105-32.
25. Binka, F. (2005). Editorial: North-South research collaborations: a move towards a true partnership? Tropical Medicine and International Health, 10(3): 207-9.
26. Black, N. (2001). Evidence based policy: proceed with care. BMC, 323: 275-8.
27. Bloor, D. (1976). Knowledge and Social Imagery. London: Routledge.
28. Bluhm, R. (2005). From hierarchy to network: A richer view of evidence for evidence-based medicine. Perspectives in Biology and Medicine, 48(4): 535-48.
29. Bockting, C.L.H., Boerema, I. and Hermens, M.L.M. (2010). Update multidisciplinaire richtlijn voor de diagnostiek, behandeling en begeleiding van volwassenen met een depressieve stoornis [Update multidisciplinary guideline for the diagnosis, treatment and guidance of adults with a depressive disorder]. GZ-Psychologie, 1(1): 40-3.
30. Bonneuil, C. (2000). Development as experiment: science and state building in late colonial and postcolonial Africa, 1930-1970. Osiris, 15: 258-81.
31. Borders, T.F., Booth, B.M., Han, X., Wright, P., Leukefeld, C., Falck, R.S., et al. (2008). Longitudinal changes in methamphetamine and cocaine use in untreated rural stimulant users: racial differences and the impact of methamphetamine legislation. Addiction, 103: 800-8.
32. Boruch, R.F. (1997). Randomised Experiments for Planning and Evaluation. A Practical Guide. London: Sage.
33. Boyd, K. (2001). Early discontinuation violates Helsinki principles. BMJ, 322: 605-6.
34. Boyer, E.W. and Shannon, M. (2005). The serotonin syndrome. New England Journal of Medicine, 352(11): 1112-20.
35. Brindle, L.A., Oliver, S.E., Dedman, D., Donovan, J.L., Neal, D.E., Hamdy, F.C., Lane, J.A. and Peters, T.J. (2006). Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU International, 98(4): 777-82.
36. Brown, P. and Zavestoski, S. (2005). Social movements in health. Oxford: Blackwell Publishing.
37. Brown, R. (1997a). Artificial experiments on society: Comte, G.C. Lewis and Mill. Journal of Historical Sociology, 10(1): 74-97.
38. Brown, R. (1997b). The delayed birth of social experiments. History of the Human Sciences, 10(2): 1-23.
39. Burns, A., Howard, R., Wilkinson, R.G. and Banerjee, S. (2005). NICE draft guidance on the anti-dementia drugs. BMJ [Online]. [Accessed 03 December 2009].
40. Busfield, J. (2006). Pills, power, people: sociological understandings of the pharmaceutical industry. Sociology, 40: 297-314.
41. Callahan, D. (1987). Setting Limits: Medical Goals in an Ageing Society. New York: Simon & Schuster.
42. Callon, M. (2004). Europe wrestling with technology. Economy and Society, 1(33): 121-34.
43. Callon, M., Lascoumes, P. and Barthe, Y. (2001). Agir dans un monde uncertain Paris: Seuil.
44. Callon, M. and Law, J. (1982). On interests and their transformation: enrolment and counter-enrolment. Social Studies of Science, 12: 615-25.
45. Callon, M. and Rabeharisoa, V. (2008). The growing engagement of emergent concerned groups in political and economic life: lessons from the French Association of Neuromuscular Disease Patients. Science, Technology & Human Values, 33(2): 230-61.
46. Cambrosio, A., Keating, P., Schlich, T. and Weisz, G. (2006). Regulatory objectivity and the generation and management of evidence in medicine. Social Science & Medicine, 63: 189-99.
47. Campbell, M., Fitzpatrick, R., Haines, A., Kinmonth, A.L., Sandercock, P., Spiegelhalter, D. and Tyrer, P. (2000). Framework for design and evaluation of complex interventions to improve health. British Medical Journal, 321(7262): 694-6.
48. Cancer Research UK (2009). Latest UK Cancer Incidence and Mortality Summary-rates. http://info.cancerresearchuk.org/prod_consump/groups/cr_common/ @nre/@sta/documents/generalcontent/crukmig_1000ast-2736.pdf. [Accessed February 2010.]
49. Carrithers, D. (1995). The enlightenment science of society. In: C. Fox, R. Porter and R. Wokler, eds., Inventing human science. 18th-century domains, Berkeley, CA: University of California Press, pp. 232-70.
50. Carroll, K.M. and Onken, L.S. (2005). Behavioral therapies for drug abuse. American Journal of Psychiatry, 162(8): 1452-60.
51. Cartwright, N. (2007). Are RCTs the Gold Standard? BioSocieties, 2(1): 11-20.
52. Chalmers, I. (1990). Underreporting research is scientific misconduct. JAMA, 263: 1405-08.
53. Chalmers, I. (1995). What do I want from health research and researchers when I am a patient? BMJ, 310: 1315-8.
54. Chalmers, I. (2005). Statistical theory was not the reason that randomisation was used in the British Medical Research Council's clinical trial of streptomycin for pulmonary tuberculosis. In: Jorland, G., Opinel, A., Weisz, G., eds. Body Counts: Medical Quantification in Historical and Sociological Perspectives. Montreal: McGill-Queens University Press, pp. 309-34.
55. Chalmers, I. (2007). The Alzheimer's Sciety, drug manufacturers, and public trust. BMJ, 335(7616): 40.
56. Chamberlain, J., Melia, J., Moss, S. and Brown, J. (1997). The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technology Assessment, 1 (3) (whole volume).
57. Chapin, F.S. (1917a). The experimental method and sociology. I. The theory and practice of the experimental method. Scientific Monthly, 4 (2): 133-44.
58. Chapin, F.S. (1917b). The experimental method and sociology. II. Social legislation is social experimentation. Scientific Monthly, 4(3): 238-47.
59. Chapple, A., Ziebland, S., Shepperd, S., Miller, R., Herxheimer, A. and McPherson, A. (2002). Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. British Medical Journal, 325: 737-41.
60. Chopra, S.S. (2003). Industry funding of clinical trials: benefit or bias? JAMA, 290(1): 113-14.
61. Collins, H.M. and Pinch, T. (1993). The Golem: What everyone should know about science, Cambridge: Cambridge University Press.
62. Consortium Richtlijnontwikkeling (2009). Richtlijnherziening van de multidisciplinaire richtlijn depressie bij volwassenen (eerste revisie).
63. Consortium Guidelines Development, 2009. Guideline change of the multidisciplinary guideline depression in adults (first revision). Utrecht: Trimbos Instituut. Available at www.ggzrichtlijnen.nl/index.php?pagina=/ richtlijn/item/pagina.php&richtlijn_id=88 [accessed 30 March 2010].
64. Cook, B. and Kothari, U. (eds.) (2001). Participation-The New Tyranny? London: Zed Press.
65. Cook, T.D. and Campbell, D.T. (1979). Quasi-experimentation. Design and Analysis Issues for Field Settings. Chicago: Rand McNally.
66. Cook, R.J. and Sackett, D.L. (1995). The number needed to treat: a clinically useful measure of treatment effect. BMJ, 310: 452-4.
67. Corrigan, O. (2003). Empty ethics: the problem with informed consent. Sociology of Health and Illness, 25(7): 768-92.
68. Coveney, J. (1988). The politics and ethics of health promotion: the importance of Michel Foucault. Health Education Research, 13(3): 459-68.
69. Crinson, I. (2004). The politics of regulation within the 'modernized' NHS: the case of beta interferon and the 'cost-effective' treatment of multiple schlerosis. Journal of Critical Social Policy, 24: 30-49.
70. Culyer, A.J. (1983). Effectiveness and efficiency of health services. Effective Health Care, 1: 7-9.
71. Culyer, A.J. and Meads, A. (1992). The United-Kingdom-effective, efficient, equitable. Journal of Health Politics, Policy and Law, 17: 667-88.
72. Daemmrich, A.A. (2004). Pharmacopolitics. Drug Regulation in the United States and Germany. Chapel Hill and London: The University of North Carolina Press.
73. Danchin, N. (2009). Correspondence: Rosuvastatin, C-reactive protein, LDL cholesterol and the JUPITER trial. The Lancet, 374: 24-5.
74. Danziger, K. (1990). Constructing the subject. Cambridge: Cambridge University Press.
75. Daston, L. and Galison, P. (2007). Objectivity. New York: Zone Books.
76. Dear, P. (2002). Experiment in science and technology studies, in S. Jasanoff (ed), Science and Technology Studies: International Encyclopedia of Social and Behavioral Sciences. New York: Elsevier. pp. 277-93.
77. Dehue, T. (2001). Establishing the experimenting society: The historical origin of social experimentation according to the randomized controlled design. American Journal of Psychology, 114(2): 283-302.
78. Dehue, T. (2002). A Dutch treat. Randomised controlled experimentation and the case of heroin-maintenance in the Netherlands. History of the Human Sciences, 15(2): 75-98.
79. Dehue, T. (2005). History of the control group. In: B. Everitt and D. Howell, eds. Encyclopedia of Statistics in the Behavioral Sciences, vol 2. Chichester, UK: Wiley.
80. Dehue, T. (2008). De Depressie-epidemie. Over de plicht het lot in eigen hand te nemen [The Depression-epidemic. On the duty to manage one's destiny]. Amsterdam: Augustus.
81. Deleuze, G. (2007). Society of Control [Accessed July 2008].
82. Department of Health. (2005). Government Response to NICE Consultation on Alzheimer's Drugs. London: DoH.
83. Despres, J.-P. (2009). Bringing JUPITER down to earth. The Lancet, 373: 1147-8.
84. Desrosières, A. (1998). The Politics of Large Numbers. A History of Statistical Reasoning. Cambridge, MA: Harvard University Press.
85. Dickersin, K. (1990). The existence of publication bias and risk factors for its occurrence. JAMA, 263(10): 1385-1359.
86. Dickersin, K., Chan, S., Chalmers, T.C., Sacks, H.S. and Smith, H. (1987). Publication bias and clinical trials. Controlled Clinical Trials, 8(4): 343-53. DIPEX. org-Patient Experiences of Health and Illness. PSA Testing module. [accessed July 2008].
87. Djulbegovic, B., Lacevic, M., Cantor, A., Fields, K.K., Bennett, C.L., Adams, J.R., Kuderer, N.M. and Lyman, G.H. (2000). The uncertainty principle and industry-sponsored research. The Lancet, 356: 635-8.
88. Donovan, J.L., Frankel, S., Faulkner, A., Gillatt, D. and Hamdy, F.C. (1999). Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the UK. British Medical Journal, 318: 299-300.
89. Donovan, J.L., Frankel, S.J., Neal, D.E. and Hamdy, F.C. (2001). Screening for prostate cancer in the UK. British Medical Journal, 323: 763-4.
90. Donovan, J.L., Mills, N., Smith, M., Brindle, L., Jacoby, A., Peters, T., Frankel, S., Neal, D., Hamdy, F. and Little, P. (2002a). Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. British Medical Journal 325: 766-70.
91. Donovan, J.L., Brindle, L. and Mills, N. (2002b). Capturing users' experiences of participating in cancer trials. European Journal of Cancer Care, 11(3): 210-14.
92. Donovan, J.L., Hamdy, F., Neal, D., Peters, T., Oliver, S., Brindle, L. et al. (2003). Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technology Assessment, 7, 14 (whole volume).
93. Doucet, M. and Sismondo, S. (2008). Evaluations of solutions to sponsorship bias. Journal of Medical Ethics, 34: 627-30.
94. Earl-Slater, A. (2002). The Handbook of Clinical Trials and Other Research, Oxon: Radcliffe Medical Press.
95. Eggers, M., Davey-Smith, G. and O'Rourke, T. (2001). The rationale, potentials and promise of systematic reviews, in M. Egger, G. Davey-Smith and D.G. Altman (eds) Systematic Reviews in Health Care, London: BMJ.
96. Elkashef, A., Rawson, R.A., Smith, E., Pearce, V., Flammino, F., Campbell, J., et al. (2007). The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction, 102 Suppl 1: 107-13.
97. Epstein, S. (1995). The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Science Technology and Human Values, 20(4): 408-37.
98. Epstein, S. (1996). Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley: University of California Press.
99. Epstein, S. (1997). Activism, drug regulation, and the politics of therapeutic evaluation in the AIDS era: A case study of ddC and the 'surrogate markers' debate. Social Studies of Science, 27(5): 691-726.
100. Epstein, S. (2007). Inclusion: The Politics of Difference in Medical Research. Chicago: University of Chicago Press.
101. Essink Bot, M.L., de Koning, H.J., Nijs, H.G., Kirkels, W.J., van der Maas, P.J. and Schroder, F.H. (1998). Short-term effects of population based screening for prostate cancer on health-related quality of life. Journal of the National Cancer Institute, 90: 925-31.
102. Evans, R., Edwards, A.G.K., Elwyn, G., Watson, E., Grol, R., Brett, J., Austoker, J. (2007). 'It's a maybe test': men's experiences of prostate specific antigen testing in primary care. British Journal of General Practice, 57: 303-10.
103. Faulkner, A. (1997). 'Strange bedfellows' in the laboratory of the NHS? An analysis of the new science of health technology assessment in the United Kingdom. In: Elston M.A. (ed.) The Sociology of Medical Science and Technology. Sociology of Health and Illness Monograph No. 3, Blackwell: Oxford, pp. 183-207.
104. Faulkner, A. (2009). Medical Technology into Healthcare and Society: A Sociology of Devices, Innovation and Governance. Chapter 5: 'The PSA test for prostate cancer: risk constructs governance?'. Basingstoke: Palgrave Macmillan.
105. Featherstone, K. and Donovan, J. (1998). Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial. British Medical Journal, 317: 1177-80.
106. Featherstone, K. and Donovan J. (2002). 'Why don't they just tell me straight, why allocate it?' The struggle to make sense of participating in a randomised controlled trial. Social Science & Medicine, 55(5): 709-19.
107. Feeman, W.E. (2009). Correspondence: Rosuvastatin, C-reactive protein, LDL cholesterol and the JUPITER trial. The Lancet, 374: 24.
108. Felt, U., Wynne, B., Callon, M. et al. (2007). Taking Knowledge Society Seriously: Report of the Expert group on Science and Governance. Brussels: Science, Economy and Society Directorate, European Commission.
109. Ferguson, N. (2004). Osteoporosis in focus. London: Pharmaceutical Press.
110. Fisher, J.A. (2009). Medical Reseach for Hire. New Brunswick, NJ: Rutgers University Press.
111. Fishman, J.R. (2004). Manufacturing Desire: The Commodification of Female Sexual Dysfunction. Social Studies of Science, 34(2): 187-218.
112. Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975). Mini-Mental State-Practical Method for Grading Cognitive State of Patients for Clinician. Journal of Psychiatric Research, 12: 189-98.
113. Food and Drug Administration. (1981). The story of the laws behind the labels. Available at www.fda.gov/AboutFDA /WhatWeDo/History/Overviews/ ucm056044.htm [accessed 8 March 2010].
114. Foucault, M. (1979). Pastoral Power and Political Reason, in Carrette, J.R. (ed.) (1999). Religion and Culture, Manchester: Manchester University Press, pp. 135-53.
115. Foucault, M. (1980). The eye of power. In: Gordon, C. (ed.). Power/Knowledge: Selected Interviews and Other Writings 1972-77. New York, Pantheon Books, pp. 146-65.
116. Fournier, J.C. (2010). Antidepressant drug effects and depression severity. A patient-level meta-analysis. Journal of the American Medical Association, 303 (1): 47-53.
117. Fox, R.C. (1957). Training for Uncertainty. In: R.K. Merton, G. Reader and P.L. Kendall (eds), The Student Physician. Cambridge: Harvard University Press, pp. 207-41.
118. Fox, R.C. (1959). Experiment Perilous: Physicians and Patients Facing the Unknown. New York: The Free Press.
119. Fox, R.C. (1980). The Evolution of Medical Uncertainty. Milbank Memorial Fund Quarterly, 58(1): 1-49.
120. Fox, R.C. (2000). Medical Uncertainty Revisited. In: G. L. Albrecht, R. Fitzpatrick and S.C. Scrimshaw (eds), The Handbook of Social Studies in Health and Medicine London: SAGE Publications, pp. 409-25.
121. Franklin, S. (2003). Ethical Biocapital: New Strategies of Cell Culture. In: S. Franklin and M. Lock (eds), Remaking Life and Death: Toward an Anthropology of the Biosciences. Santa Fe, NM: School of American Research Press, pp. 97-128.
122. Fraser (MP). (2006). House of Commons Written Answers for 14 Dec 2006-Cancer Treatment. http://www.parliament.the-stationery-office.com/pa/ cm200607/cmhansrd/cm061218/text/61218w0061.htm. [Accessed March 2010].
123. Freidson, E. (1984). The changing nature of professional control. Annual Review of Sociology, 10: 1-20.
124. Freidson, E. (1988). Profession of Medicine: A Study of the Sociology of Applied Knowledge. Chicago: University of Chicago Press.
125. Friedli, L. (2009). Mental Health, Resilience and Inequalities. WHO Europe, available at www.euro.who.int/document/e92227.pdf [accessed on 30 March 2010].
126. Fullerton, H.R. and Bishop, E.L. (1933). Improved rural housing as a factor in malaria control. South. Medical Journal, 26: 465-8.
127. Galton, F. (1872). Statistical inquiries into the efficacy of prayer. Fortnightly Review 12: 124-35.
128. Galton, F. (1889). Human variety. Journal of the Anthropological Institute, 18: 401-19.
129. Garcia de Tena, J. (2009). Rosuvastatin, C-reactive protein, LDL cholesterol and the JUPITER trial. The Lancet, 374: 24.
130. Garratini, S. and Chalmers, I. (2009). Patients and the public deserve big changes in the evaluation of drugs. British Medical Journal, 338: 804-6.
131. Geissler, P.W. and Pool, R. (2006). Popular concerns with medical research projects in Africa-a critical voice in debates about overseas research ethics. Tropical Medicine and International Health, 11(7): 975-82.
132. Geissler, P.W., Kelly, A., Imokhuede, B. and Pool, R. (2008). 'He is now like a brother, I can even give him my blood'-relational ethics and material exchanges in a malaria vaccine 'trial community' in The Gambia. Social Science and Medicine, 67(5): 696-709.
133. Gezondheidsraad (2006). Verzekeringsgeneeskundige protocollen. Algemene inleiding, overspanning, depressieve stoornis [Health Council, 2006. Health Insurance protocols. General introduction, stress, depressive disorder]. Den Haag: Gezondheidsraad, available at www.gezondheidsraad.nl/sites/default/ files/200622_site3.pdf [accessed 30 March 2010].
134. Gibbons, M. (1999). Science's New Social Contract with Society. Nature 402: C81-84.
135. Gibbons, M., Limoges, C., Schwartzman, S., Nowotny, H., Trow, M. and Scott, P. (1994). The New Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies. Newbury Park, CA.: Sage.
136. Giddens, A. (1991). The Consequences of Modernity, Stanford, CA: Stanford University Press.
137. Gimming, J.E. and Slutsker, L. (2009). House screening for malaria control. The Lancet, 374: 945-55.
138. Godwin, M., Ruhland, L., Casson, I., MacDonald, S., Delva, D., Birtwhistle, R., Lam, M. and Seguin, R. (2003). Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Medical Research Methodology 3: 28.
139. Goffman, E. (1959). The Presentation of Self in Everyday Life. New York: The Overlook Press.
140. Graf, C., Battisti, W.P., Bridges, D., Bruce-Winkler, V., Conaty, J.M., Ellison, J.M., Field, E.A., Gurr, J.A., Marx, M-E., Patel, M., Sanes-Miller, C., Yarker, Y.E. for the International Society for Medical Publication Professionals (2009). Good publication practice for communicating company sponsored medical research: the GPP2 Guidlelines. British Medical Journal 339: b4330.
141. Grant, C.H.I., Cissna, K.N. et al. (2000). Patients' perceptions of physicians communication and outcomes of the accrual to trial process. Health Communication, 12(1): 23-39.
142. Gray, A., and S. Harrison, eds. (2004). Governing Medicine: Theory and Practice. Maidenhead and New York: Open University Press.
143. Greenhalgh, T. (1997). How to read a paper: papers that report drug trials, British Medical Journal, 315: 480-83.
144. Grol, R. and Grimshaw, J. (2003). From best evidence to best practice: effective implementation of change in patients' care. The Lancet, 362: 1225-30.
145. Grossman, J. and MacKenzie, F.J. (2005). The randomized controlled trial: gold standard or merely standard. Perspectives in Biology and Medicine, 48(4): 516-34.
146. Guyatt, G.H., Sackett, D.L. and Cook, D.J. (1993). Users' guides to the medical literature. II. How to use an article about therapy or prevention. Journal of the American Medical Association, 270 (21): 2598-601.
147. Hacking, I. (1990). The Taming of Chance. New York: Cambridge University Press.
148. Halpern, S.A. (2004). Lesser Harms: The Morality of Risk in Medical Research. Chicago: University of Chicago Press.
149. Ham, C. and Roberts, G. (eds) (2003). Reasonable Rationing: International Experience of Priority Setting in Health Care. Maidenhead: Open University Press.
150. Hayden, C. (2003). When Nature Goes Public: The Making and Unmaking of Bioprospecting in Mexico. Princeton: Princeton University Press.
151. Hayden, C. (2007). Taking as Giving. Social Studies of Science, 37(5): 729-58.
152. Healy, D. (1997). The Antidepressant Era. Cambridge: Harvard University Press.
153. Healy, D. (2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York: New York University Press.
154. Healy, D. (2009). Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice. Transcultural Psychiatry, 46(1): 16-37.
155. Heimer, C.A. (2007). Old inequalities, new diseases: HIV/AIDS in Sub-Saharan Africa. Annual Review of Sociology, 33: 551-77.
156. Helms, R. (2002). Guinea Pig Zero. An Anthology of the Journal for Human Research Subjects. New Orleans: Garrett County Press.
157. Hewitson, P. and Austoker, J. (2005). Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing. BJU International, 95(S3): 16-32.
158. Hlatky, M.A. (2008). Expanding the orbit of primary prevention-moving beyond JUPITER, New England Journal of Medicine, 359(21): 2280-82.
159. Holmes D.R. and Marcus G.E. (2005). Cultures of expertise and the management of globalisation: toward the re-functioning of ethnography. In: Ong, A. and Collier S.J. (eds) Global Assemblages: Technology, Politics and Ethics as Anthropological Problems. Oxford: Blackwell Publishing. pp. 236-52.
160. Holton, G. (1978). Subelectrons, presuppositions, and the Millikan-Ehrenhaft dispute. Historical Studies in the Physical Sciences, 9: 161-224.
161. Horton, R. (1995). The rhetoric of research. British Medical Journal, 310: 985-7.
162. Horton, R. (1997). Conflicts of interest in clinical research: opprobium or obsession? The Lancet, 349: 1112-1113.
163. Horton, R. (2002). Postpublication criticism and the shaping of clinical knowledge. Journal of the American Medical Association, 287: 2843-7.
164. Horton, R. (2003a). Statin wars: why Astra Zeneca must retreat. The Lancet, 362: 1341.
165. Horton, R. (2003b). Editor's reply. The Lancet, 362: 1856.
166. Ioannidis, J.P.A. (2008). Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine, 3 (14). Available at www.peh-med.com/content/ pdf/1747-5341-3-14.pdf [accessed 30 March 2010].
167. Irving, P. (2005). Anger at drugs removal. The Times, 10 March 2005.
168. Irwin, A. and Michael, M. (2003). Science, social theory and public knowledge Milton Keynes: Open University Press.
169. Jarvis, M. (2004). Psychodynamic Psychology: Classical Theory and Contemporary Research. London: Thomson.
170. Jasanoff, S. (2005). Designs on Nature: Science and Democracy in Europe and the United States. Princeton: Princeton University Press.
171. Jenkins, V., Fallowfield, L.J., Souhami, R.L., Sawtell, M. (1999). How do doctors explain randomised clinical trials to their patients? European Journal of Cancer, 35: 1187-93.
172. Jonvallen, P. (2005). Testing Pills, Enacting Obesity: The Work of Localizing Tools in a Clinical Trial. Department of Technology and Social Change. Linköping, Linköping University. Unpublished PhD thesis.
173. Kachur, S.P., Abdulla S., Barnes K., Mshinda H., Durrehim, D., Kitua, A., Bloland, P. (2001). Complex and large trials of pragmatic malaria interventions. Tropical Medicine International Health, 6: 324-5.
174. Kaptchuck, T. (2001). The double-blind, randomised, placebo-controlled trial: Gold standard or golden calf? Journal of Clinical Epidemiology, 54(6): 541-9.
175. Katz, J. (2002). From how to why: on luminous description and causal inference in ethnography (part 2). Ethnography, 3: 63-90.
176. Keating, P. and Cambrosio, A. (2003). Biomedical platforms. realigning the normal and the pathological in late-twentieth-century medicine. Cambridge, MA: MIT Press.
177. Keating, P. and Cambrosio, A. (2005). Risk on trial: the interaction of innovation and risk factors in clinical trials. In: T. Schlich and U. Throhler (eds), The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context, London: Routledge. pp. 225-41.
178. Keating, P. and Cambrosio, A. (2007). Cancer clinical trials: The emergence and development of a new style of practice. Bulletin of the History of Medicine, 81(1): 197-223.
179. Kelly, A. (in press). Pragmatic clinical research: remember Bambali: evidence, ethics and the co-production of truth. In: P.W. Geissler and C. Molyneux (eds) Ethics and Ethnography. Oxford: Berghahn.
180. Kernick, D.P. (2003). Correspondence: Statin Wars. The Lancet, 362: 1855.
181. Killeen, G.F. (2003). Following in Soper's footsteps: northeast Brazil 63 years after eradication of Anopheles gambiae. Lancet Infectious Disease, 3: 663-6.
182. Kimmelman, J. (2007). The therapeutic misconception at 25: treatment, research and confusion. Hastings Center Report, 37(6): 36-42.
183. Kirby M., Ameh, D., Bottomley, C., Green, C. Jawara, M., Milligan P.J., Snell, P., Conway, D., Lindsay, S.W. (2009). Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. The Lancet, 374: 998-1009.
184. Kirsch, I., et al. (2008). Initial severity and antidepressant benefits: A meta analysis of data submitted to the Food and Drug Administration. PloS Medicine, 5(2): 260-8. Available at www.plosmedicine.org/article/info:doi/10.1371/journal. pmed.0050045 [accessed 8 March 2010].
185. Knorr Cetina, K. (1999). Epistemic Cultures. How the Sciences make Knowledge. Cambridge, MA and London, UK: Harvard University Press.
186. Kritiek P. and Campion E.W. (2009). JUPITER Clinical Directions-polling results, NEJM, 360: 10.
187. Kuhn, T.S. (1962). The Structure of Scientific Revolutions. Chicago: University of Chicago Press.
188. Kurer, O. (1991). John Stuart Mill. The Politics of Progress. New York: Garland.
189. Lagakos, S.W. (2006). The challenge of subgroup analyses-reporting without distorting. New England Journal of Medicine, 354: 1667-9.
190. Lairumbi, G.M., Molyneux, S., Snow, R.W., Marsh, K., Peshu, N., English, M. (2008). Promoting the social value of research in Kenya: Examining the practical aspects of collaborative partnerships using an ethical framework. Social Science & Medicine, 67(5): 734-47.
191. Lakoff, A. (2005). Pharmaceutical Reason: Knowledge and Value in Global Psychiatry. Cambridge: Cambridge University Press.
192. Lakoff, A. (2007). The right patients for the drug: managing the placebo effect in antidepressant trials. BioSocieties, 2(1): 57-71.
193. Landelijke Stuurgroep multidisciplinaire richtlijnontwikkeling, 2005a. Multidisciplinaire richtlijnen schizofrenie en depressie gereed. Een feestelijke presentatie [National Steering Committe Development Multidisciplinary Guidelines, 2005a. Multidisciplinary guidelines schizofrenia and depression finished. A festive presentation]. Nieuwsbrief GGZ-R, 4, (7). Available at www.ggzrichtlijnen.nl/uploaded/docs/Nieuwsbrief GGZ-R no. 7.pdf [accessed 8 March 2010]. Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling, 2005b.
194. Multidisciplinaire richtlijn depressie [National Steering Committe Development Multidisciplinary Guidelines, 2005b. Multidisciplinary guideline depression]. Utrecht: Trimbos Instituut. Available at www.ggzrichtlijnen.nl/uploaded/docs/ AF0605SAMENVRichtlDepressie.pdf [accessed 8 March 2010].
195. Langley, C., Gray, S., Selley, S., Bowie, C., Price, C. (2000). Clinicians' attitudes to recruitment to randomised trials in cancer care: a qualitative study. Journal of Health Services Research Policy, 5(3): 164-9.
196. Latour, B. (1987). Science in Action, Cambridge MA: Harvard University Press.
197. Latour, B. (1993). We Have Never Been Modern. Cambridge, MA: Harvard University Press.
198. Latour, B. (1998). From the world of science to the world of research? Science, 280: 208-09.
199. Latour, B. (2004). Politics of Nature: How to Bring the Sciences into Democracy. Harvard: Harvard University Press.
200. Latour, B. and Woolgar, S. (1979). Laboratory Life: The Construction of Scientific Facts. Princeton, NJ: Princeton University Press.
201. Leach, M., Fairhead, J. and Small, M. (2004). Childhood Vaccination and Society in the Gambia: Public Engagement with Science and Delivery. IDS Working Papers. Brighton: University of Sussex.
202. Leach, M., Scones, I. and Wynne, B. (eds), (2005). Science and Citizenship, London: Zed Press.
203. Leahey, E. (2008). Overseeing research practice: the case of data editing. Science, Technology and Human Values, 33: 605-30.
204. Leichsenring, F. (2005). Are psychoanalytic and psychodynamic psychotherapies effective? A review. International Journal of Psychoanalysis, 86(3): 841-68.
205. Lewis, C.G. (1852, reprint 1974). A Treatise on the Methods of Observation and Reasoning in Politics. Vol. 1. New York: Arno Press.
206. Lezaun, J. and Soneryd, L. (2007). Consulting citizens: technologies of elicitation and the mobility of publics. Public Understanding of Science, 16: 279-97.
207. Lidz, C.W., Appelbaum, P.S., Grisso, T. and Renaud, M. (2004). Therapeutic misconception and the appreciation of risks in clinical trials. Social Science and Medicine, 58(9): 1689-97.
208. Light, D.W. (1991). Professionalism as a countervailing power. Journal of Health Politics, Policy and Law, 16: 499-506.
209. Light, D. and Levine, S. (1988). The changing character of the medical-profession-a theoretical overview. Milbank Quarterly, 66: 10-32.
210. Light, D.W. and Hughes, D. (2001). Introduction: A sociological perspective on rationing: power, rhetoric and situated practices. Sociology of Health & Illness, 23: 551-69.
211. Lindegger, G., Milford, C., Slack, C., Quayle, M., Xaba, X. and Vardas, E. (2006). Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. Journal of Acquired Immune Deficiency Syndrome, 43(5): 560-66.
212. Lindsay, S.W., Jawara, M., Paine, K., Pinder, M., Walraven, G.E.L., Emerson, P.M. (2003). Changes in house design reduce exposure to malaria mosquitoes. International Journal of Tropical Health, 8: 512-17.
213. Loveman, E., Green, C., Kirkby, J., Takeda, A., Picot, J., Bradbury, J., Payne, E. and Clegg, A. (2005). The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease. Southhampton: Southampton Health Technology Assessment Centre.
214. Lovie, A.D. (1979). The analysis of variance in experimental psychology: 1934-1945. British Journal of Mathematical and Statistical Psychology, 32(2): 151-78.
215. Lurie P. and Wolfe, S.M. (1997). Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine, 337: 847-9.
216. Macklin, R. (2004). Double standards in medical research in developing countries. Cambridge Law and Ethics Series, No. 2. Cambridge: Cambridge University Press.
217. Maeseneer, J.M.D., Van Driel, M.L., Gren, L.A. and Van Weel, C. (2003). The need for research in primary care. The Lancet, 362: 1314-19.
218. Marks, H.M. (1997). The Progress of Experiment. Science and Therapeutic Reform in the United States, 1900-1990. New York: Cambridge University Press.
219. Marks, H.M. (2000). Trust and mistrust in the marketplace: statistics and clinical research, 1945-1960. History of Science, 38: 343-55.
220. Marres, N. (2007). The issues deserve more credit: Pragmatist contributions to the study of public involvement in controversy. Social Studies of Science, 37(5): 759-80.
221. Marres, N. (2009). Testing powers of engagement: green living experiments, the ontological turn and the undoability of involvement. European Journal of Social Theory, 12(1): 117-33.
222. May, C. (2006). Mobilizing modern facts: Health Technology Assessment and the politics of evidence. Sociology of Health & Illness, 28: 513-32.
223. May, C. and Ellis, N.T. (2001). When protocols fail: technical evaluation, biomedical knowledge, and the social production of 'facts' about a telemedicine clinic. Social Science and Medicine, 53: 989-1002.
224. McCall, W.A. (1923). How to Experiment in Education. New York: Macmillan.
225. McDonald, R. (2002). Street-level bureaucrats? Heart disease, health economics and policy in a primary care group. Health Social Care Community, 10: 129-35.
226. McDonald, A.M., Knight, R.C., Campbell, M.K., Entwistle, V.A., Grant, A.M., Cook, J.A. (2006). What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials, 7:9 online doi:10.1186/1745-6215-7-9.
227. McGoey, L. (2007). On the will to ignorance in bureaucracy. Economy and Society 36: 212-35.
228. McGoey, L. (2009). Pharmaceutical controversies and the performative value of uncertainty, Science as Culture 18(2): 151-67.
229. McGoey, L. (2010). Profitable failure: antidepressant drugs and the triumph of flawed experiments. History of the Human Sciences, 23(1): 58-78.
230. McGuire, A., Henderson, G., Mooney, G. (1986). The Economics of Health Care: An Introductory Text. London: Routledge.
231. McPherson, K. (1994). The best and the enemy of the good: randomised controlled trials, uncertainty, and assessing the role of patient choice in medical decision making. Journal of Epidemiology and Community Health, 48: 6-15.
232. Mechanic, D. (1995). Dilemmas in rationing health care services: the case for implicit rationing, British Medical Journal, 310: 1655-9.
233. Medawar, C. et al. (2002). Paroxetine, panorama and user reporting of ADRs: Consumer intelligence matters in clinical practice and post-marketing drug surveillance. International Journal of Risk & Safety in Medicine, 15: 161-169. Available at www.socialaudit.org.uk/ijrsm-161-169.pdf [accessed 9 March 2010].
234. Medical Research Council PR06 collaborators (2004). Early closure of a randomised controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial. BJU International, 94(9): 1400-1.
235. Milewa, T. (2006). Health technology adoption and the politics of governance in the UK. Social Science & Medicine, 63: 3102-12.
236. Mill, J.S. (1843, reprint 1973). A System of Logic. Toronto: University of Toronto Press.
237. Miller, D. (2003). The Virtual Moment. Journal of the Royal Anthropological Institute, 9(1): 57-5.
238. Miller, F.G. and Rosentstein, D.L. (2003). The therapeutic orientation to clinical trials. New England Journal of Medicine, 348(14): 1383-6.
239. Mills, N., Donovan, J.L., Smith, M., Jacoby, A., Neal, D.E., Hamdy, F.C. (2003). Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Controlled Clinical Trials, 24(3): 272-82.
240. Mirowski, P., and Van Horn, R. (2005). The contract research organization and the commercialization of scientific research. Social Studies of Science, 35(4): 506-48.
241. Moerman, D.E. (2002). Meaning, Medicine and the 'Placebo effect'. Cambridge: Cambridge University Press.
242. Mol, A. (2008). The Logic of Care. Health and the Problem of Patient Choice. London: Routledge.
243. Molyneux, S. and Geissler, P.W. (2008). Ethics and the ethnography of medical research in Africa. Social Science & Medicine, 67(5): 685-95.
244. Moreira, T. (2005). Diversity in clinical guidelines: the role of repertoires of evaluation. Social Science and Medicine, 60(9): 1975-85.
245. Moreira, T. (2006). Sleep, health and the dynamics of biomedicine. Social Science & Medicine, 63(1): 54-63.
246. Moreira, T. (2007). Entangled evidence: knowledge making in systematic reviews in healthcare. Sociology of Health & Illness, 29(2): 180-97.
247. Moreira, T. (2008). Continuous positive airway pressure machines and the work of coordinating technologies at home. Chronic Illness, 4(2): 102-9.
248. Moreira, T. (2009). Testing promises: truth and hope in drug development and evaluation in Alzheimer's Disease. In: Ballenger, J.F., Whitehouse, P.J., Lyketsos, C., Rabins, P. and Karlawish, J.H.T. (eds) Do we Have a Pill for That? Interdisciplinary Perspectives on the Development, Use and Evaluation of Drugs in the Treatment of Dementia. Baltimore: Johns Hopkins University Press.
249. Moreira, T., May, C. and Bond, J. (2009). Regulatory objectivity in action: MCI and the collective production of uncertainty. Social Studies of Science, 39(5): 665-90.
250. Moreira, T. and Palladino, P. (2005). Between truth and hope: on Parkinson's disease, neurotransplantation and the production of the 'self'. History of the Human Sciences, 18(3): 55-82.
251. National Institute of Clinical Excellence (2001). Donepezil, Rivastigmine, Galantamine for the Treatment of Alzheimer's Disease. London: NICE.
252. National Institute of Health and Clinical Excellence (2002). Guidance on Cancer Services. Improving Outcomes in Urological Cancers. The Manual. London: National Institute for Health & Clinical Excellence. [Accessed September 2007.]
253. National Institute of Health and Clinical Excellence (2006). Appraisal Consultation Document: Donepezil, Rivastigmine, Galantamine and Memantine for the Treatment of Alzheimer's Disease. London: NICE.
254. Naylor, C.D., Chen, E. and Strauss, B. (1996). Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Annals of Internal Medicine, 117: 916-21.
255. Norheim, O.F. (2002). The role of evidence in health policy making: a normative perspective. Health Care Analysis, 10: 309-17.
256. Nowotny, H., Scott, P., Gibbons, M. (2001). Re-thinking Science: Knowledge and the Public in an Age of Uncertainty. Cambridge: Polity Press.
257. Oliver, S.E., May, M.T. and Gunnell, D. (2001). International trends in prostatecancer mortality in the 'PSA ERA'. International Journal of Cancer, 92: 893-8.
258. Oliver, S.E., Donovan, J.L., Peters T.J., Frankel, S., Hamdy, F.C. and Neal, D.E. (2003). Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU International, 91(4): 331-6.
259. Orenstein, A.J. (1912). Screening as an antimalaria measure. A contribution to the study of the value of screened dwellings in malaria regions. Proceedings of Canal Zone Medical Association, 5:12-18.
260. Orr, J. (2006). Panic Diaries: A Genealogy of Panic Disorder. Durham: Duke University Press.
261. Orr, L.L. (1999). Social Experiments. Evaluating Public Programs with Experimental Methods. London: Sage.
262. Oudshoorn, N. (1993). United we stand-the pharmaceutical industry, laboratory and clinic in the development of sex-hormones into scientific drugs, 1920-1940. Science, Technology and Human Values, 18(1): 5-24.
263. Parker, G., Anderson, I.M. and Haddad, P. (2001). Clinical trials of antidepressant medications are producing meaningless results. British Journal of Psychiatry, 183: 102-04.
264. Parsons, T. (1951). The Social System. Glencoe, IL: The Free Press.
265. Petryna, A. (2002). Life Exposed: Biological Citizens after Chernobyl. Princeton: Princeton University Press.
266. Petryna, A. (2007). Clinical Trials Offshored: On Private Sector Science and Public Health. Biosocieties, 2(1): 21-40.
267. Petryna, A. (2009). When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton, NJ: Princeton University Press.
268. Petryna, A. and Kleinman, A. (2006). The pharmaceutical nexus: an introduction. In: A. Petryna, A. Lakoff, and A. Kleinman (eds) Global Pharmaceuticals: Ethics, Markets, Practices. Durham, NC: Duke University Press.
269. PloS Medicine editors. (2009). Ghostwriting: the dirty little secret of medicine that just got bigger. PloS Medicine, 6(9): 1-2 Available at www.plosmedicine. org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000156 [accessed 8 March 2010].
270. Porter, T.M. (1986). The Rise of Statistical Thinking, 1820-1900. Princeton: Princeton University Press.
271. Porter, T.M. (1995). Trust in Numbers. The Pursuit of Objectivity in Science and Public Life. Princeton: Princeton University Press.
272. Public Accounts Committee (2005). Cancer-The Patient's Experience. PAC Publications. Uncorrected Evidence, House of Commons HC 485-i.
273. Rabeharisoa, V. and Callon, M. (2002). The involvement of patients' associations in research. International Social Science Journal, 54(1): 57.
274. Radley, D.C., Finkelstein, S.N. and Stafford, R.S. (2006). Off-label prescribing among office-based physicians. Archives of Internal Medicine, 166(9): 1021-26.
275. Rajan, K.S. (2002). Biocapital as an emergent form of life: speculations on the figure of the experimental subject. In: Novas, C. and Gibbons, S. (eds) Biosocialities, Genetics and The Social Sciences. London: Routledge.
276. Rajan, K.S. (2003). Genomic capital: public cultures and markets logics of corporate biotechnology. Science as Culture, 12(1): 87-121.
277. Rajan, K.S. (2006). Biocapital: The Constitution of Postgenomic Life. Durham CA: Duke University Press.
278. Rapley, T., May, C. et al. (2006). Doctor-patient interaction in a randomised controlled trial of decision-support tools. Social Science & Medicine 62(9): 2267-78.
279. Rasmussen, N. (2004). The moral economy of the drug company-medical scientist collaboration in interwar America. Social Studies of Science, 34: 161-86.
280. Rasmussen, N. (2005). The drug industry and clinical research in interwar America: three types of physician collaborator. Bulletin of the History of Medicine, 79: 50-80.
281. Rawlins, M.D. and Culyer, A.J. (2004). National Institute for Clinical Excellence and its value judgments. British Medical Journal, 329: 224-7.
282. Richards, E. (1991). Vitamin C and Cancer: Medicine or Politics? New York: St Martin's Press.
283. Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al., on behalf of the JUPITER Trial Study Group. (2009). Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, The Lancet, 373: 1175-82.
284. Rip, A. (1986). Controversies as informal technology-assessment. Knowledge-Creation Diffusion Utilization, 8: 349-71.
285. Roll, J.M. (2007). Contingency management: an evidence-based component of methamphetamine use disorder treatments. Addiction, 102(Suppl. 1): 114-40.
286. Rose, D. & Blume, S. (2003). Citizens as users of technology: an exploratory study of vaccines and vaccination. In: Oudshoorn, N., Pinch, T. (eds). How Users Matter: The Co-construction of Users and Technology. Cambridge, MA: MIT Press, pp. 103-31.
287. Rosenberg, C.E. (2002). The tyranny of diagnosis. Specific entities and individual experience. The Milbank Quarterly, 80(2): 237-60.
288. Rosenberg, C.E. (2003). What is a disease? Bulletin of the History of Medicine, 77(3): 491-505.
289. Rosenstein, R. and Parra, D. (2009). Correspondence: Rosuvastatin, C-reactive protein, LDL cholesterol and the JUPITER trial. The Lancet, 374: 24.
290. Royal College of Psychiatry. (2006). Implementation of the NICE Guidance on Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Sisease. London: RCP.
291. Rucci, A.J. and Tweney, R.D. (1980). Analysis of variance and the 'second discipline' of scientific psychology: A historical account. Psychological bulletin, 87: 166-84.
292. Ryan, S., Williams, I. and Mciver, S. (2007). Seeing the NICE side of cost effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Economics, 16: 179-93.
293. Sackett, D.L. (1979). Bias in analytic research. Journal of Chronic Disease, 32(1-2): 51-63.
294. Sackett, D., Straus, S.E., Richardson, W.S., Rosenberg, W. and Haynes, R.B. (2000). Evidence-based Medicine. London: Churchill Livingstone.
295. SAMHSA. (2007). Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies.
296. Sana, M. and Weinreb, A. (2008). Insiders, outsiders, and the editing of inconsistent survey data. Sociological Methods & Research, 36: 515.
297. Savage P., Bates C., Abel P. and Waxman, J. (1997). British urological surgery practice: 1. Prostate cancer. British Journal of Urology, 79(5): 749-54.
298. Schaffer, S. (2005). Sky, heaven and the seat of power. In: B. Latour and P. Weibel (eds), Making Things Public. Karlsruhe and Cambridge MA: ZKM/MIT Press. pp. 120-25.
299. Schofield, C.J. and White, G.B. (1984). Engineering against insect-borne diseases in the domestic environment. House design and domestic vectors of disease. Transactions of Royal Society Tropical Medicine Hygiene, 78: 285-92.
300. Schröder, F., Hugosson, J., Roobol, M.J., and 20 others. (2009). Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine, 360(13): 1320-28.
301. Selley, S., Donovan, J., Faulkner, A., Coast, J., Gillatt, D. (1997). Diagnosis, management and screening of early localised prostate cancer. Health Technology Assessment, 1(2): 1-96 (whole volume).
302. Shapin, S. and Schaffer, S. (1985). Leviathan and the Air-Pump. Hobbes, Boyle and Experimental Life, Princeton: Princeton University Press.
303. Shuchman, M. (2007). Commercializing clinical trials: risks and benefits of the CRO boom. New England Journal of Medicine, 357(14): 1365-68.
304. Simes, R.J. (1986). Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology, 4(10): 1529-41.
305. Sismondo, S. (2007). Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine, 4(9): e286.
306. Sismondo, S. (2008). How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine, 66: 1909-14.
307. Sismondo, S. (2009). Ghosts in the machine. Publication planning in the medical sciences. Social Studies of Science, 39: 171-98.
308. Smith, R. (1991). Where is the wisdom? The poverty of medical evidence. BritishMedical Journal, 303(6806): 798-9.
309. Snedecor, G.W. (1936). The improvement of statistical techniques in biology. Journal of the American Statistical Association, 31: 690-701.
310. Sniderman, A.D. (2009). Correspondence: Rosuvastatin, C-reactive protein, LDL cholesterol and the JUPITER trial. The Lancet, 374: 24.
311. Star, S.L. (1991). Invisible work and silenced dialogues in knowledge representation. In: Eriksson, I. V., Kitchenham, B.A. and Tijdens, K.G. (eds) Women, work and computerization: Understanding and overcoming bias in work and education. Amsterdam: North-Holland.
312. Star, S.L. (1991). Power, technologies and the phenomenology of conventions: on being allergic to onions. In Law, J. (ed.). A Sociology of Monsters: Essays on Power, Technology and Domination. London: Routledge.
313. Stengers, I. (2000). The Invention of Modern Science, Minneapolis/London: University of Minnesota Press.
314. Strathern, M. (2000). Accountability and ethnography. In: M. Strathern (ed.), Audit Cultures: Anthropological Studies in Accountability, Ethics, and the Academy, London: Routledge, pp. 279-304.
315. Strathern, M. (2002). Externalities in comparative guise. Economy and Society, 31: 205-67.
316. Strathern, M. (2004 [1991]). Partial Connections. Updated edition. Walnut Creek: Altamira Press.
317. Strauss, A.L. (1993). Continual Permutations of Action. New York: Walter de Gruyter, Inc.
318. Street, Alice. n.d. Research in the clinic: scientific emplacement and medical failure, Conference Paper Publics of Public Health, Kilifi, Kenya, December 7th-11th 2009.
319. Tanenbaum, S.J. (1994). Knowing and acting in medical research: the epistemological politics of outcomes research. Journal of Health Politics, Policy and Law, 19: 27-44.
320. The Lancet (2006). Rationing is essential in tax-funded health systems. The Lancet, 368: 1394.
321. Thornton, H. (2008). Patient and public involvement in clinical trials. British Medical Journal, 336: 903-04.
322. Timmermans, S. and Alison, A. (2001). Evidence-based medicine, clinical uncertainty, and learning to doctor. Journal of Health and Social Behavior, 42(4): 342-59.
323. Timmermans, S. and Berg, M. (2003). The Gold Standard: The Challenge of Evidence-based Medicine and Standardization in Health Care. Philadelphia, PA: Temple University Press.
324. Timmermans, S. and McKay, T. (2009). Clinical trials as treatment option: bioethics and health care disparities in substance dependency. Social Science & Medicine, 69(12): 1784-90.
325. Timmermans, S. and Tavory, I. (2007). Advancing ethnographic research through grounded theory practice. In: A. Bryant and K. Charmaz (eds), Handbook of Grounded Theory, London: Sage. pp. 493-513.
326. Tomlin, Z., Donovan, J. and Dieppe, P. (2007). Opening the black box of equipoise in randomised controlled trials. Presentation at BSA Medical Sociology Conference, Liverpool, September 2007.
327. Torgerson, D.J. (1998). Understanding controlled trials: what are pragmatic trials? British Medical Journal, 319: 285.
328. Torgerson, D.J., Klaber-Moffett, J. and Russell, I.T. (1996). Patient preferences in randomised trials: threat or opportunity? Journal of Health Services Research and Policy, 1(4):194-7.
329. Toynbee, P. (2006). Attacks on the decisions over the value of drugs are being used as a battering ram to break support for the NHS. The Guardian, 24 October 2006.
330. Traynor, M. (2009). Indeterminacy and technicality revisited: how medicine and nursing have responded to the evidence based movement. Sociology of Health and Illness, 31(4): 494-507.
331. Tunis, S.R. (2003). Practical clinical trials: increasing the value of clinical research. Journal of the American Medical Association, 290: 1634-2.
332. Turner, E.H., et al., (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3): 252-60.
333. UK Clinical Research Collaboration (2010). UK Clinical Research Collaboration. http://www.ukcrc.org/. [Accessed February 2010].
334. Vailly, J. (2006). Genetic screening as a technique of government: The case of neonatal screening for cystic fibrosis in France. Social Science & Medicine, 63(12): 3092-101.
335. Wager, E., Tooley, P.J.H. et al. (1995). How to do it: Get patients' consent to enter clinical trials. British Medical Journal, 311: 734-42.
336. Watson, E., Jenkins, L., Bukach, C. and Austoker, J. (2002). The PSA Ttest and Prostate Cancer: Information for Primary Care. NHS Cancer Screening Programmes: Sheffield, [Accessed July 2007]
337. Webster, A. (2007). Reflections on reflexive engagement. Response to Nowotny and Wynne. Science, Technology and Human Values, 32(5): 608-15.
338. Weinstein, M.C. and Stason, W.B. (1977). Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine, 296: 716-21.
339. Wilkinson, R.G. and Pickett, K.G. (2009). The Spirit Level. Why More Equal Societies Almost Always do Better. London: Allen Lane.
340. Will, C. (2007). The alchemy of clinical trials. Biosocieties, Special Issue, 2(1): 85-99.
341. Will, C. (2009). Identifying effectiveness in "the old old": principles and values in the age of clinical trials. Science, Technology and Human Values, 34: 607-28.
342. Williams, I., McIver, S., Moore, D. and Bryan, S. (2008). The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technology Assessment, 12: iii, ix-x, 1-175.
343. Williams, T., May, C., Mair, F., Mort, M. and Gask, L. (2003). Normative models of health technology assessment and the social production of evidence about telehealth care. Health Policy, 64(1): 39-54.
344. Winslow, B.T., Voorhees, K.I. and Pehl, K.A. (2007). Methamphetamine abuse. American Family Physician, 76(8): 1169-74.
345. Winterton, R. (2006). Written Answers to Questions [17 Mar 2006]-Prostate Cancer. Hansard Volume No. 443 Part No. 127. http://www.publications. parliament.uk/pa/cm200506/cmhansrd/vo060317/text/60317w17. htm#60317w17.html_spnew5. [Accessed June 2008].
346. Wood, M., Ferlie, E. and Fitzgerald, L. (1999). Achieving clinical behaviour change: a case of becoming indeterminate. Social Sciences and Medicine, 47(11): 1720-38.
347. World Health Organisation. (1982). Manual on Environmental Management for Mosquito Control, with Special Emphasis on Malaria Vectors. WHO Offset Publication No. 66, World Health Organisation.
348. World Health Organisation. (2002). Safety of Medicines. A Guide to Detecting and Reporting Adverse Drug Reactions. Why Health Professionals Need to Take Action. Geneva: World Health Organisation. Available at http://whqlibdoc. who.int/hq/2002/WHO_EDM_QSM_2002.2.pdf [accessed 8 March 2010].
349. Worrall, J. (2002). What evidence in evidence-based medicine. Philosophy of Science, 69: S316-S330.
350. Wozniak, P. (2003). Correspondence: Statin Wars. The Lancet, 363: 1855.
351. Wright, D., Sathe, N. and Spagnola, K. (2007). State Estimates of Substance Use from the 2004-2005 National Surveys on Drug Use and Health. Rockville, MD: Office of Applied Studies.
352. Yusuf, S., Lonn, E. and Bosch, J. (2009). Lipid lowering for primary prevention. The Lancet, 373: 1151-55.
353. Zorgverzekeraars Nederland en GGZ Nederland, (2008). In-en Verkoopgids DBC GGZ 2009 [Netherlands Health Insurers and Mental Health Organisations, 2008. Acquisition and Sales Guide of Diagnosis-Treatment Combinations in Mental Health 2009]. Zeist/Amersfoort: Zorgverzekeraars Nederland and GGZ Nederland. Available at www.zn.nl/leeszaal/zn_uitgaven/znuitgaven/in_ en_verkoopgids_dbc_ggz_2009.asp [accessed 30 March 2010].